Oslo, Norway, 25 January 2010 - Algeta ASA (OSE:ALGETA), the cancer therapeutics
company, announces it's financial calendar for 2010


19. Feb.        Presentation of the annual accounts (08:00 CET)

22. April        General meeting

07. May        Presentation of first quarter report (09:45 CET)

13. Aug.        Presentation of second quarter report (09:45 CET)

12. Nov.        Presentation of third quarter report (09:45 CET)


The presentations will be held at Hotel Continental, Oslo. Algeta reserves the
right to revise the dates. The calendar is available in the report for the third
quarter 2009 and on www.algeta.com.



                                      ###


For further information, please contact


 Andrew Kay, CEO                        +47 2300 7990 / +47 4840 1360 (mob)
 Øystein Soug, CFO                      +47 2300 7990 / +47 9065 6525 (mob)
                                        post@algeta.com


 International media enquiries:         +44 207 638 9571
 Mark    Swallow/Helena   Galilee/David mark.swallow@citigatedr.co.uk
 Dible                                  
 Citigate Dewe Rogerson


 US investor enquiries:                 +1 646 378 2928
 Jessica Lloyd                          jlloyd@troutgroup.com
 The Trout Group                        





About Algeta
Algeta  ASA is a cancer therapeutics company built on world-leading, proprietary
technology.   Algeta   is   developing  a  new  generation  of  targeted  cancer
therapeutics  (alpha-pharmaceuticals) that harness the unique characteristics of
alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's  lead alpha-pharmaceutical candidate, Alpharadin (based on radium-223),
has  blockbuster potential  for treating  bone metastases  arising from multiple
major  cancer  types,  owing  to  its  bone-targeting  nature,  potent  efficacy
(therapeutic   and   palliative)   and   benign,  placebo-like  safety  profile.
Development  of Alpharadin is most  advanced targeting bone metastases resulting
from  hormone-refractory prostate cancer (HRPC), and it entered an international
phase  III clinical  trial (ALSYMPCA)  in mid-2008  based on compelling clinical
results  from a comprehensive phase II program. This trial is currently open for
recruitment.

In September 2009, Algeta entered into an global agreement with Bayer Healthcare
AG  for  the  development  and  commercialization  of Alpharadin. As part of the
agreement,  Algeta  retains  an  option  to  co-promote Alpharadin in the United
States and to share profits from future sales.

Algeta    is    also    developing    other    technologies    for    delivering
alpha-pharmaceuticals.   These   include  methods  to  enhance  the  potency  of
therapeutic  antibodies and other  tumor-targeting molecules by  linking them to
the  alpha particle emitter  thorium-227. The Company  is headquartered in Oslo,
Norway,  and was founded  in 1997. Algeta listed  on the Oslo  Stock Exchange in
March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement
This  news release  contains forward-looking  statements and  forecasts based on
uncertainty,  since they relate to events  and depend on circumstances that will
occur  in the future and which, by their  nature, will have an impact on results
of  operations and  the financial  condition of  Algeta. There  are a  number of
factors  that could cause  actual results and  developments to differ materially
from  those  expressed  or  implied  by these forward-looking statements. Theses
factors  include,  among  other  things,  risks  associated  with  technological
development,  the risk that  research & development  will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable  and profitable business  deals, the risk  of non-approval of patents not
yet  granted and difficulties  of obtaining relevant  governmental approvals for
new products.

 ###


This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1376950]





    Financial calendar 2010: http://hugin.info/134655/R/1376950/338082.pdf